The vaccine, developed by Janssen Pharmaceutical, a company in the group, completed the first and second phases of clinical trials and the immune response it elicits in the body lasted “at least 71 days” in participants aged 18 to 55, according to provisional data released today .
Still during the month of January, the group will release the results of the third phase of trials, starting from a provisional analysis in which the candidate vaccine “was generally well tolerated in all participants”.
After taking a dose of the vaccine, 90% of the participants developed neutralizing antibodies 29 days after inoculation and 100% between 18 and 55 years old had antibodies on the 57th day, a reaction that continued 71 days after receiving the vaccine.
Also during this month, the company will reveal data on the immune response triggered by the vaccine in people over 65.
If the single-shot vaccine is proven to be effective and safe, Janssen will ask the US drug authority, the FDA, for an emergency use authorization, following the same request from other regulators around the world.
This vaccine uses a genetic approach similar to the Pfizer-BioNtech and Moderna vaccines already in application, instructing the body to produce and recognize the protein that SARS-CoV-2 uses to penetrate cells.
However, in the Janssen vaccine the gene for this protein is associated with a common adenovirus, usually associated with colds, which is deactivated and can enter cells, but cannot replicate or cause disease.
The covid-19 pandemic has already claimed at least 1,979,596 deaths resulting from more than 92.3 million cases of infection worldwide, according to a report by the French agency AFP.
In Portugal, 8,236 people have died of 507,108 confirmed cases of infection, according to the most recent bulletin from the Directorate-General for Health.
*The article has been translated based on the content of Jornal de Negócios by www.jornaldenegocios.pt. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!